Compare Moderna, Inc. (MRNA) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs NextEra Energy, Inc. — how do they compare? Moderna, Inc. trades at $195.76 (market cap $78.65B), while NextEra Energy, Inc. trades at $77.33 (market cap $161.39B). The key difference: NextEra Energy, Inc. is far larger — about 2.1× Moderna, Inc.'s market cap, and NextEra Energy, Inc. pays a 3.22% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and NextEra Energy, Inc. for 83 Days on average.
| MRNA | NEE | |
|---|---|---|
Market Cap | $78.65B | $161.39B |
Volume | 37,373,437 | 11,780,955 |
Sector | Health | Utilities |
52-Week High | $203.46 | $97.88 |
52-Week Low | $22.36 | $75.49 |
Typical Hold Time | 59 Days | 83 Days |
Enterprise Value | $74.80B | $268.72B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
NextEra Energy (NEE) trades at $77.06, down 1.05% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a 32.4% net income margin and consistent earnings beats in recent quarters, though it missed in Q4 2025. Recent news highlights growth initiatives, including a $22.3 billion energy infrastructure project in Texas announced on September 30, 2026.
The outlook remains positive with a consensus price target of $96.00, implying 25% upside, supported by robust cash flow and profitability. Risks include rising debt levels, with debt-to-asset ratio increasing to 47.6% in 2025, and sensitivity to interest rate changes. Analyst sentiment is bullish with 66.66% buy ratings, but technical weakness near 52-week lows warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
